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Abstract: Interferon alfa2 (IFN-α2) is a parenterally administered cytokine used to treat 
patients with Hepatitis C and B, and malignancy. Interferon (INF) has a relatively high rate of 
central nervous system (CNS) adverse effects, including agitation, depression, fatigue, cognitive 
dysfunction, suicidal thought and drug craving. Using functional magnetic resonance imaging 
(fMRI) we studied patients with Hepatitis C virus (HCV) infection who were not more than 
mildly clinically depressed at baseline for their CNS reaction to IFN-α2. During fMRI, patients 
underwent visual stimulation with pictures designed to induce feelings of depression. In the two 
patients who became clinically depressed or markedly anxious while on treatment with interferon, 
but not in patients who did not experience these effects, there was a signiﬁ  cant activation in 
speciﬁ  c areas of the brain known to be involved with depression, along with an increase above 
baseline in the Beck Depression Scale for the patient who developed INF-induced depression. 
The activation pattern differed from that previously observed for endogenous depression, indi-
cating that INF-induced depression may differ in its underlying neuropathology. Functional 
magnetic resonance imaging can be an important tool in understanding and monitoring for (INF 
and other) medication-induced CNS effects, and response to treatment.
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Introduction
Although the number of Americans with HCV infection has declined about ten-fold 
from the 1980s to 2001, estimates (McQuillan 2004) show that as many as four million 
persons have been infected with HCV. No vaccine is available to prevent Hepatitis C, 
unlike for Hepatitis A and B, and carriers can transmit the disease (via blood and body 
ﬂ  uids) throughout the remainder of their life. Hepatitis C has an enormous effect on 
morbidity and mortality. Perhaps eighty percent of infected people in the United States 
show signs of chronic infection, which over a period of 5–20 years may lead to liver 
cirrhosis (20%) and or liver cancer (Pagliaro 1999). Approximately 25% of patients 
with cirrhosis will die from hepatic failure or require liver transplantation; HCV is 
responsible for about one-third of all liver transplants in the United States.
Interferons are a family of cytokines – biologic mediators produced by leukocytes 
that have therapeutic application for a wide spectrum of disease states, including cancer 
and infectious diseases such as Hepatitis C and B. Interferon alpha 2 (IFN-α2) is a 
cytokine which is endogenously produced by leukocytes upon viral infection, explain-
ing why IFN-α2 has proven therapeutic effectiveness against chronic Hepatitis C and 
B infection.
Many patients receiving INF experience ﬂ  u-like symptoms early in treatment, but 
these symptoms typically diminish with continued treatment. Patients also can experience 
GI disturbances, arthralgias, and injection site reactions (Prescribing Information).Neuropsychiatric Disease and Treatment 2007:3(5) 656
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Interferon alpha 2 has been shown to have a wide range 
of neuromodulatory properties in the CNS. These include the 
regulation of endocrine systems such as upregulation of the 
hypothalamic-pituitary-adrenal axis. Interferon alpha 2 can 
modulate behavior, brain activity, temperature, feeding pat-
tern and endogenous opioid activity. Neuropsychiatric effects 
from IFN-α2 can include apathy, anxiety, cognitive changes, 
irritability, depression, suicidal thoughts, drug craving and 
mania (Prescribing Information; Onyike 2004).
Although not all patients with HCV develop neuropsy-
chiatric symptoms when treated with INF, investigators have 
reported that between 10% and 40% of patients experience 
depressive symptoms. Overall, interferon dosage must be 
reduced in many patients and discontinued in as many as 
40% of patients because of severe side effects. Other than 
avoiding use of INF in individuals with signiﬁ  cant underlying 
depression, there is currently no way to predict whether an 
individual will respond to interferon by developing adverse 
neuropsychiatric effects. It will therefore be of immense 
value to be able to predict and monitor in a quantiﬁ  able man-
ner a clinically signiﬁ  cant depressive response to interferon 
(and other therapeutic modalities) in patients prior to the 
initiation of treatment. The purpose of this ongoing study 
is to apply an imaging methodology using fMRI to detect 
and monitor neuropsychiatric adverse effects of interferon 
(and other drugs) treatment for HCV (and other diseases), 
and monitor the response to interventions to treat these neu-
ropsychiatric adverse effects.
Methodology
Patients with Hepatitis C infection, and who were candidates 
for therapy with INF-α2 were screened. Those subjects with-
out excluding medical history or disqualifying medical exam 
were explained the study purpose and design, risks and ben-
eﬁ  ts, and asked to give informed consent for participation in 
the Institutional Review Board (IRB)-approved protocol: Use 
of fMRI to Predict Neurologic Adverse Effects of Interferon 
Used to Treat Patients with Hepatitis C and HIV-Infected 
Patients Treated with Sustiva. Patients received interferon 
and other treatment as part of their usual care for Hepatitis 
C. Patients did not automatically receive a new prescription 
for antidepressants as a prophylactic action prior to therapy 
with INF.
Data acquisition
Testing (Beck Depression Scale, medical history, fMRI) was 
performed at baseline (prior to INF treatment), and at six 
weeks of therapy, or sooner if the patient developed clinically 
signiﬁ  cant psychiatric symptoms. The Beck was the only 
psychiatric rating scale used, and structured interviews were 
not used to generate psychiatric diagnoses.
Patients were seen routinely at 2, 4, 6, 8 weeks of treat-
ment, and monthly thereafter, unless their medical condition 
required otherwise. At each visit, patients were interviewed, 
questioned about anxiety, depression, insomnia, agitation, 
suicidal thoughts, drug craving and other psychiatric symp-
toms, and a subjective assessment of the onset of mood 
disorders was made.
To perform functional magnetic resonance imaging, 
each test subject lay within a GE Cigna 3-T Signa 11X 
Excite MRI scanner, wearing a phased array whole head 
coil, mounted with a 45 degree mirror. This arrangement 
allowed test subjects to see images displayed onto a rear 
projection screen positioned by their feet. Functional MR 
imaging was performed while viewing of the test stimuli 
in order to capture functional data (Marks 2006). A short 
localizer MRI scan was performed to verify that the ﬁ  eld of 
view was within the skull, and that there were no “ghost” 
images. A high-resolution full volume structural MRI scan 
was then obtained for each subject, using fast SPGR imaging 
(146, 1.0-mm thick axial slices, no spaces, TR = 8, TE = 3.2, 
FOV = 24 cm, 256 £ 256 matrix). These T1-weighted images 
provided detailed anatomical information for registration and 
3-D normalization to a standard atlas.
Changes in the blood oxygen level dependent MRI signal 
were measured using a gradient-echo echoplanar sequence. 
Continuous functional Neuroimaging (fMRI) scans lasted 
110 seconds each. EPI parameters were: TE 35, TR 2000, 
multiphase screen, 55 phases per location, interleaved, ﬂ  ip 
angle 90, delay after acquisition-minimum. Using a visual 
stimulus package, color photographs were presented in a 
mini-block design while Neuroimaging was performed. In a 
typical session, after a 4 second lead-in time, a blank screen 
was displayed for 4 seconds, then the picture of interest for 
4 seconds, and this was repeated for the scan time.
Test stimuli
Visual stimuli (four pictures of a depressing nature, Figures 
1–4) were generated by PC using PowerPoint (Microsoft). 
The pictures were projected onto a rear projection screen 
placed at the foot of the test subject, who viewed the screen 
by means of a mirror system mounted on the head coil.
Data analysis
The fMRI scan volumes were motion-corrected and spatially 
smoothed in-plane, normalized and analyzed using MedX, Neuropsychiatric Disease and Treatment 2007:3(5) 657
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as described elsewhere (Marks et al 2006). The data was 
analyzed for the presence of neuroimaging activation that 
has been shown to correspond to depression.
Results
Two of the four HCV patients (AA and BB) imaged (Table 1), 
did not experience clinical depression nor was there an increase 
observed in the Beck Depression scores at six weeks of treatment 
when compared to baseline. For these persons, the baseline fMRI 
(Figure 5) did not differ in the number of activation areas from 
that seen at six weeks of treatment with interferon (Figure 6). 
This indicated that INF itself is does not cause an activation of 
the brain which was detectable using our system.
One individual (CC) did experience signiﬁ  cant depression 
while receiving interferon, with a corresponding increase (17–29) 
in Beck Depression Scale (Table 1). She had experienced depres-
sion in the past, although those episodes were not as severe as the 
depression that occurred during interferon treatment. Her sisters 
have also experienced depression. Patient CC had a hysterectomy 
24 years previously and was on hormone replacement therapy.
Another patient (DD) experienced signiﬁ  cant agitation 
without depression from treatment with INF, and did not have 
a change (20–16) in Beck Depression Scale (Table 1). Patient 
DD had an oophrectomy 3 years before this study and her 
last menstrual period was a year before entering treatment 
with interferon. She did not have a past history of clinically 
signiﬁ  cant depression or agitation, and there was no family 
history of psychiatric illness.
The fMRI activation map for patient CC (who developed 
depression), after only two weeks of therapy with INF, 
Figures1
Subject Initials
AA BB CC DD
Age 67 64 47 42
Sex M F F F
CNS-active meds No No No No
H/O IVDU Yes No Yes Yes
Suicidal thoughts No No No No
Initial Hep C Viral load 283,000 11,000,000 3,750,000 3,270,000
Previous H/O any 
psychiatric illness
No No Yes No
H/O substance abuse Yes No Yes Yes
F/H psych illness N N Sisters N
Interferon Peg-Intron Pegasys Peg-Intron Pegasys
BDS before INF 2 14 17 20
BDS on INF 5 13 29 16
Mood disorder No No Depression Anxiety/agitation
Reversible n/a n/a Yes Yes
Abbreviations: BDS, Beck Depression scale, before and after onset of clinical depression; CNS-active drugs, amphetamine, cocaine, antidepressants, others; f/h, family his-
tory; h/o, history of; IVDU, intravenous drug abuse.
Table 1 Demographic characteristics of study subjects
Figure 2
Figure 3 Figure 4Neuropsychiatric Disease and Treatment 2007:3(5) 658
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showed signiﬁ  cant increase in areas of activation (Figure 8, 
and Table 2) when compared to baseline (Figure 7). The 
activation map (not shown) for patient DD, who developed 
signiﬁ  cant anxiety but no depression, showed also increased 
areas of activation (Table 2). A limitation of the study was 
the use of only the Beck psychiatric rating scale and not 
utilizing a structured interview to generate psychiatric diag-
noses. We will incorporate these additional techniques in 
our follow-up studies.
Those individuals who did not become depressed during 
INF use had less than a ﬁ  ve-point rise of the Beck Depression 
Scale (BDS) during INF use. The patient (CC) who devel-
oped signiﬁ  cant depression on INF had mild depression at 
baseline (Beck score 17) and experienced signiﬁ  cant and 
incapacitating depression (Beck 29) during INF use, requir-
ing a reduction in INF dose. After the dose reduction, the 
symptoms of depression resolved, and use of antidepres-
sants was not required. A second person (DD) experienced 
signiﬁ  cant increased in agitation/anxiety from INF therapy, 
but not depression on questioning. There was no increase in 
the Beck Depression Scale, but there was a change in fMRI 
response that correlated with CNS symptoms. This patient 
Figure 8 Functional MRI for patient CC at 2 weeks of therapy, showing multiple 
areas of interferon-induced CNS activation A representative section of the brain 
MRI of one of the subjects (CC) who did develop CNS symptoms (clinically signiﬁ  -
cant depression) after interferon therapy, in this case after only two weeks of INF. 
Visual stimulus #4 (Figure 4) was used to generate this scan. There is a signiﬁ  cant 
increase in multiple activation areas (red areas) over baseline (Figure 9, Table 2). 
There was also a signiﬁ  cant increase in the Beck Depression Scale (Table 1) over 
baseline.
Figure 7 Baseline functional MRI of patient patient CC, who developed interferon-
induced depression after two weeks of treatment. A representative section of the 
baseline brain MRI of one (CC) of the initial test subjects who did develop CNS 
symptoms (clinically signiﬁ  cant depression) after only two weeks of interferon 
therapy. Visual stimulus #4 (Figure 4) was used to generate this scan. The lack of 
signiﬁ  cant activation is consistent with that of individuals who did not experience 
depression at baseline (Figure 5) or after interferon treatment (Figure 6).
Figure 6 Functional MRI after six weeks of interferon in a representative subject 
who did not show interferon-induced activation. A representative section of the 
brain MRI at six weeks of one (AA) of the test subjects who did not develop any 
CNS symptoms after six weeks of interferon therapy. Visual stimulus #2 (Figure 2) 
was used to generate this scan. There are no signiﬁ  cant areas of brain activation 
(red) over baseline (Figure 5). There was no signiﬁ  cant change in the Beck Depres-
sion scale. This lack of activation was seen in all subjects who did not develop 
clinical depression while on treatment with INF.
Figure 5 Functional MRI at baseline. A representative section of the baseline brain 
MRI of one (AA) of the test subjects who did not develop any CNS symptoms 
after six weeks of interferon therapy. Visual stimulus #2 (Figure 2) was used to gen-
erate this scan. There are only a few areas of activation (red). This pattern of lack 
of activation was seen in all test subjects who did not develop clinical depression 
while on treatment with INF.Neuropsychiatric Disease and Treatment 2007:3(5) 659
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Broadman 
Area Brain Region patient CC CC CC DD DD
Fu 
(Table 2)
Visual 
stimulus 234 41
1
2
3
4 precentral gyrus
5
6 premotor cortex
7 precuneus
8 sup frontal gyrus
9
10
L MID 
FRONTAL 
GYRUS
11
12
13 L insula
14
15
16
17
18 sup frontal gyrus
19
20
21
LMiddle
temporal gyrus 
22
L Superior 
temporal gyrus 
23
mid cingulate 
gyrus
24
ant, mid and post 
cingulate gyrus
25
Table 2 Activation areas for patients who developed clinically signiﬁ  cant depression (CC) or agitation (DD) while on INF therapy, 
compared to patients with MDD (Fu et al 2004, Table 2
(Continue)Neuropsychiatric Disease and Treatment 2007:3(5) 660
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responded to an anxiolytic medication, but did not require a 
reduction in dosage of INF.
Discussion
Even though we present preliminary data on a limited number 
of subjects, several points are of interest:
1.  The data indicate that it is possible to detect clinically 
signiﬁ  cant medication-induced depression and anxiety 
with a fMRI assay,
2.  The MRI scan veriﬁ  es that patients who did not develop 
clinical depression/anxiety as determined by the Beck 
Depression Scale and physician assessment, also did not 
develop activation of those areas of the brain known to 
correlate with clinical depression,
3.  This preliminary data supports not giving prophylactic 
medications (selective serotonin reuptake inhibitors 
(SSRI)) to all patients who are going to receive interferon 
therapy.
26
27
parahipposcampal
gyrus
28
29
30
parahipposcampal
gyrus
31
post cingulate
gyrus
32
33
ant cingulate
gurys
34
35
36
37 inf temp cortex
38
39
L superior 
temporal gyrus
40
L inf parietal 
cortex
41
42
43
44
45 R inferior frontal
46
R mid frontal 
cortex
47
L Inferior frontal
gyrus
Table 2 (Continued)
Activation areas with fMRI from two patients who developed clinically signiﬁ  cant and reversible depression (CC) and agitation/anxiety (DD) from interferon, compare to 
those with endogenous MDD studied Fu et al (2004, Table 2). Patients viewed photos of a depressing nature (Figures 1–4) during fMRINeuropsychiatric Disease and Treatment 2007:3(5) 661
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In pharmaceutical development and in clinical practice, 
it is important to study the potential for medication-induced 
neurologic adverse effects. There have been a very limited 
number of studies using MRI on the effects of drugs on 
the brain. Functional MRI studies can be used to identify 
areas in the brain with increased metabolic responses, 
indicating increased activity. One example has been the 
effect of levodopa in drug-naïve Parkinsons patients 
(Buhmann 2003).
Apart from its antiviral activity, IFN has been shown to 
have a wide range of neuromodulatory properties in CNS. 
For example, studies in experimental animals have shown 
that IFN-α decreases dopamine in the brain (Shuto 1997). 
INF are known (Prescribing Information) to be related to a 
wide range of neurologic adverse effects including aggressive 
behavior, apathy, anxiety, cognitive changes, depression, 
irritability, and in some individuals, suicidal thought/ide-
ation, suicide, homicidal ideation, drug craving, psychoses, 
hallucinations, bipolar disorders, and mania. Although not 
all patients with HCV develop neuropsychiatric symptoms, 
most published references cite an incidence of depression 
of 10% and 40% (Prescribing Information; Meyers 1991; 
Pavol 1995). Pegylate IFN-α used in the treatment of chronic 
Hepatitis C has itself been associated with a signiﬁ  cantly 
lower incidence of depression in comparison to unmodiﬁ  ed 
IFN-α (Fried, Shiffman, Reddy et al 2002). Russo et al (2005) 
found that irritability in patients with HCV being treated with 
interferon was associated with decreased plasma tryptophan 
levels which may lead to attenuated peripheral and central 
serotonergic neurotransmission.
High dose IFN-α 2 can cause neuropsychological 
deﬁ  cits, with slowing of cognitive processes, diminished 
executive skills and memory difﬁ  culties (Capuron 2005). An 
“adynamic state” may occur, with loss of cognitive, verbal, 
and motor spontaneity, incentive, and interest (Meyers 1991; 
Pavol 1995). These symptoms are consistent with a frontal-
subcortical dysfunction, an area found by Fu et al (2004) to 
be favorably affected by antidepressants.
Peripherally given IFN-α2 has signiﬁ  cant effects on 
cerebral glucose metabolism in human subjects, which 
predominate in the prefrontal cortex and co-vary along with 
depression scores (Juengling 2000). In fact, the changes in 
prefrontal cortical activity might be interpreted as a “vulner-
ability factor” for the development of depressive symptom-
atology in patients treated with IFN-α2.
Several risk factors are thought to increase the prob-
ability of emergent psychiatric comorbidity during IFN-α 
treatment (Edlin 2001; Fried 2002; Dieperink 2003). Those 
factors include: a previous history of any psychiatric illness, 
a history of substance abuse, a family history of psychiat-
ric illnesses, and a history of suicidal ideation, and these 
risk factors were monitored for in our patients population. 
Applying these criteria for the four persons reported herein 
(Table 1), there appeared to have been a low risk for devel-
oping psychiatric adverse effects from use of INF, yet two 
patients did!
Various researchers (Douglas 2005; Raison 2005) have 
observed that individuals who experienced significant 
increases in depressive symptoms during peginterferon 
(IFN)-a/ribavirin therapy were less likely to clear hepati-
tis C from the blood. Speciﬁ  cally, failure to clear virus at 
24 weeks of therapy was associated with a 20-point or greater 
increase in depressive symptoms, with viral genotype Type 
1, and with ribavirin dose assignment. This presents another 
impetus to better understand the role of CNS adverse effects 
from INF.
Functional MRI
Functional magnetic resonance imaging (fMRI) studies can 
be used to identify areas in the brain with increased metabolic 
responses, indicating increased neural activity. The purpose 
of this pilot study was to evaluate the use of fMRI as a clini-
cal predictive tool which can observe the neuropsychiatric 
effects of interferon, and to correlate these MRI-identiﬁ  ed 
changes with symptoms of depression.
Table 3 Areas of common activation: Fu et al (2004) (MDD, 
major depressive disorder) and INF-induced depression and 
agitation
Broadman
Area
3
5
6 premotor cortex
21
L Middle temporal
gyrus
22
L Superior
temporal gyrus 
23
mid cingulate
gyrus
24
ant, mid and post
cingulate gyrus
39
L superior
temporal gyrusNeuropsychiatric Disease and Treatment 2007:3(5) 662
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Researchers have shown that functional neuroimaging 
provides the potential of identiﬁ  cation and treatment of 
Hepatitis C patients who develop neuropsychiatric symptoms 
upon interferon treatment (Matthews 2004; Weissenborn 
2004). One area of possible difﬁ  culty in data analysis when 
studying the effects of pharmacological agents with fMRI 
is that various medications (including that under study, and 
concurrent meds), may interfere with the very mechanisms 
that give rise to the fMRI signal (Salmeron 2002). This could 
occur if a medication altered the coupling of neural activ-
ity with regional cerebral blood ﬂ  ow and/or the extraction 
of oxygen from blood, or caused local or global vascular 
changes unrelated to neural activity.
The mood disorders induced in our two patients more 
likely were due to a physiologic effect of INF, rather than 
due just to the presence of INF alone. The activation seen on 
fMRI after treatment in two patients (CC and DD) with INF 
was not present at baseline. The symptoms reversed upon 
dose reduction (CC, depression) or addition of an anxiolytic 
(DD, anxiety). Two other patients (AA and BB) reported in 
this paper who were treated with INF (and in fact most of our 
patients at the clinic), did not develop complaints of a mood 
disorder, did not show changes in their Beck Depression 
scale, did not show increased activation in this fMRI study, 
and did not show signs of a mood or affect change on their 
regularly scheduled visits while undergoing treatment with 
INF. Further, because we were not able to discern activation 
by fMRI in our patients with no complaints (of depression, 
anxiety, agitation, insomnia, suicidal thought or drug crav-
ing), the lack of complaint (indicator of a mood disorder) 
may be equivalent to the absence of even sub-clinical INF-
induced brain activation.
Previous studies of fatigue and depressive symptoms in 
various medical and psychiatric conditions by functional 
neuroimaging suggest future directions for research that 
may increase understanding of the speciﬁ  c neural substrates 
of neuropsychiatric side effects associated with HCV and 
interferon treatment. Functional brain imaging techniques 
have contributed greatly to the general understanding of the 
brain circuits that may be disrupted when neuropsychiatric 
symptoms are experienced by patients with major depressive 
disorder, multiple sclerosis, and chronic fatigue syndrome. 
The anterior cingulated cortex and the prefrontal cortex have 
been implicated frequently in the development of fatigue and 
depressive symptoms in various medical and psychiatric con-
ditions. The dorsal anterior cingulated is intimately involved 
in cognitive processes such as response inhibition and error 
processing, and is also involved in modulation of the auto-
nomic nervous system (Capuron 2005). Dysfunction of the 
anterior cingulated cortex has been associated with the devel-
opment of neuro-psychiatric symptoms in several psychiatric 
and medical conditions. Functional subdivisions have also 
been identiﬁ  ed within the prefrontal cortex, a structure that is 
critically involved in the regulation of mood and affect.
Evidence from functional neuroimaging studies supports 
the role of the prefrontal cortex in mediating fatigue and 
depressive symptoms in various conditions. Many functional 
neuroimaging studies of major depressive disorder (MDD) 
used PET or fMRI (Juengling 2000) and have described 
altered brain activation in the dorsolateral prefrontal cortex 
and the dorsal anterior cingulate cortex. Hyperactivation of 
these structures have been consistently demonstrated in major 
depressive disorder. Functional MRI studies are needed to 
further investigate the identiﬁ  ed role of the anterior cingulate 
cortex in interferon-induced depression (Capuron 2005). 
Hyperactivation in the ventral anterior cingulated cortex has 
been shown to predict future antidepressant treatment response 
in MDD. Speciﬁ  c investigation of this structure in subjects who 
are taking interferon may allow prospective identiﬁ  cation of 
patients at risk for interferon-induced depression and initiation 
of prophylactic treatment for these patients.
In addition to the clinical elements detailed above, 
depression can be associated with interpersonal difﬁ  culties 
related to abnormalities in affective facial processing. Using 
this marker, Fu et al (2004) studied using fMRI those brain 
systems known to be activated by sad facial affect processing 
in patients with depression. They note that neurocognitive 
systems involved in identifying affective facial expressions 
in healthy individuals include:
1.  The fusiform face area in the ventral occipitotemporal 
cortex, which shows a selective response for faces;
2.  The superior temporal sulcus, which is responsive to 
mouth and eye movements involved in facial expres-
sions; and
3.  The amygdala (usually the left amygdala), which shows 
a selective response to emotional facial expressions such 
as fear, sadness, anger, and disgust.
In their study, Fu et al (2004) identified nineteen 
medication-free, acutely symptomatic patients satisfying 
DSM-IV criteria for unipolar major depressive disorder 
by age, sex, and IQ. These subjects were matched with 19 
healthy volunteers. After the baseline assessment, patients 
received the SSRI antidepressant, ﬂ  uoxetine hydrochloride, 
20 mg/d, for eight weeks. Average activation and differential 
response to variable affective intensity were estimated in 
each fMRI time series. Brain regions were identiﬁ  ed by Neuropsychiatric Disease and Treatment 2007:3(5) 663
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fMRI which demonstrated a main effect of group (depressed 
vs healthy subjects) and a group-time interaction (attribut-
able to antidepressant treatment). The average activation 
(capacity) and differential response to variable affective 
intensity (dynamic range) were estimated in each fMRI 
time series. Brain regions were identiﬁ  ed that demonstrated 
a main effect of group (depressed vs. healthy subjects) and 
a group-time interaction (attributable to antidepressant 
treatment).
Fu et al (2004) found:
1.  An enhanced sad facial affect–processing capacity in 
the left medial temporal, ventral striatal, and insular 
regions,
2.  Enhanced capacity for activation in patients compared 
with healthy volunteers at baseline, which normal-
izes in the course of eight weeks of antidepressant 
treatment, and
3.  Attenuated capacity of activation at eight weeks com-
pared with baseline.
There was increased capacity in the patients compared 
with the healthy comparison subjects in the following regions 
of the left brain:
1.  Hippocampus extending to amygdala and parahippo-
campal gyrus, and
Table 4 Areas of non-overlap. Fu et al (2004) (MDD) yes, INF no
21
L Middle temporal
gyrus
26
32
33
ant cingulated
gyrus
36
38
Broadman 
Area
Figures 9, 10, 11 Three dimensional bubble plots of combined areas of activation prepared for test subjects CC (Figures 9) and DD (Figure 10). For comparison, Figure 
11 presents endogenous depression activation areas from Fu et al (2004). Distinct patterns of activation were seen for drug-induced (Figure 9) and endogenous (Figure 11) 
depression and for agitation (Figure 10).
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2.  Hypothalamus, ventral striatum (putamen/globus palli-
dus), insula, caudate nucleus, thalamus, dorsal cingulate 
gyrus, and inferior parietal cortex.
A negative correlation existed between antidepressant 
exposure–related changes in facial affect–processing capacity 
and the dynamic range of response. The overall capacity for 
sad facial affect processing was reduced and the dynamic 
range of response in prefrontal cortex was increased. Overall, 
Fu et al (2004) concluded that:
1.  Antidepressant treatment reduces left limbic, subcorti-
cal, and neocortical capacity for activation in depressed 
subjects and increases the dynamic range of the left 
prefrontal cortex.
2.  Changes in anterior cingulated function were associated 
with symptomatic improvement,
3.  fMRI may be a useful surrogate marker of antidepressant 
treatment response.
Three dimensional bubble plots of combined areas of acti-
vation were prepared for test subjects, as shown in Figures 9 
and 10. For comparison, Figure 11 presents depression activa-
tion areas from Fu et al (2004). Distinct patterns of activation 
were seen for depression and for agitation. We also did not ﬁ  nd 
comparative activation areas between INF-induced depression 
(Figure 9) and endogenous MDD (Figure 11).
The differences in areas of the brain activated may point 
to signiﬁ  cant differences between depression which is endog-
enous in nature from medication-induced depression.
We identiﬁ  ed in our system several anatomic areas of 
brain activation in the two patients in our preliminary studies 
who developed signiﬁ  cant depression or anxiety during INF 
therapy. Although we identiﬁ  ed areas of overlap (Table 2), in 
general the activation pattern we observed does not correspond 
well to those noted by Fu et al (2004, their Table 2) in their 
study of the treatment of non-medication induced endogenous 
MDD. Table 3 lists areas of the brain showing common activa-
tion in our model and that of Fu et al (2004).
On the other hand, there were signiﬁ  cant areas of non-
overlap, with activation noted by Fu et al (2004) but not in 
our model (Table 4).
There were also signiﬁ  cant areas of non-overlap (Table 5), 
with activation in our model, but not that of Fu et al (2004).
The model we have developed for INF-induced depres-
sion/anxiety has wide application, and we are planning 
on extending our studies in INF, and apply the techniques 
to other medications, including the antidepressants and 
the amphetamine-like drugs used to treat attention deficit 
Table 6 Activation across images Patient CC showed brain activation above baseline while viewing visual stimulations 2,3,4, while 
patient DD showed activation with pictures 1 and 4
Patient
CC
Depression
XX X
Patient
DD
Anxiety
XX
7 Precuneus
8 sup frontal gyrus
9
10
L mid frontal 
gyrus
17
18 sup frontal gyrus
19
31
post cingulated
gyrus
40
L inferior parietal
cortex
42
44
45 R inferior frontal
46
R mid frontal
cortex
Broadman
Area
Table 5 Areas of non-overlap. INF yes, Fu et al (2004) no.Neuropsychiatric Disease and Treatment 2007:3(5) 665
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Broadman
Area Brain Region   patient  CC 
DD
Visual stimulus  44  
1
2
3
4 precentral gyrus
5
6 premotor cortex
7 precuneus
8 sup frontal gyrus
9
10
L MID FRONTAL 
GYRUS 
11
12
13 L insula
14
15
16
17
18 sup frontal gyrus
19
20
21
LMiddle temporal
gyrus
22
L Superior temporal
gyrus
23 mid cingulate gyrus
24
ant, mid and post
cingulate gyrus
25
26
27
28
29
Table 7 Similarity between two patients in areas of brain activation while viewing visual stimulation #4
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hyperactivity disorder (ADHD). Of interest, the patient 
(DD) who developed clinically significant anxiety did not 
show a corresponding increase in Beck Depression Scale, 
but did show signiﬁ  cant activation in several brain regions 
above that seen at baseline. This indicates that fMRI can 
be more sensitive in detecting clinically significant CNS 
adverse effects of medication than a written instrument 
such as the Beck Depression Scale. We are investigat-
ing further the relationship between written measures of 
CNS adverse effects of medication and corresponding 
physiologic (fMRI) brain activation. Another area we are 
exploring is the relationship between the intensity of the 
CNS adverse effect of medication which is experienced, 
and the intensity, pattern, persistence and response to 
therapy (dose modification, use of SSRI and other medi-
cations) as measured by fMRI.
These preliminary data indicate that drug-induced depres-
sion may be fundamentally different in terms of areas of 
brain activation from that of endogenous depression. In fact, 
when one considers the potential psychopathology in patients 
with HCV under treatment with INF, it is a wonder that the 
observed rate of depression in patients infected with HCV is 
not higher than that reported. Some of the over 280 patients in 
our clinic with HCV have an underlying depressive or anxi-
ety disorder, and are former illicit drug users (IV or others, 
including cocaine). As a group, they are often symptomatic of 
their underlying infection (weak, nauseous, abdominal pain, 
decreased appetite …) probably from ongoing liver inﬂ  am-
mation, and CNS effects of chronic HCV infection itself. On 
top of all this, their exposure to INF creates another layer of 
brain activation, as illustrated in our research, heightening 
the risk for depression. Because INF-associated depression 
may be different in actual psychopathology from endogenous 
depression, the optimal prophylaxis and treatment may differ 
in many ways (including use of SSRI) from that for MDD.
One of our patients (CC) experienced INF-induced depres-
sion, while the other (DD) developed INF-induced agitation/anxi-
ety. There was a great deal of overlap of the areas of the brain 
activated in these two patients (Figures 9, 10, and Table 2), not 
allowing for distinguishing by activation pattern. All patients 
viewed the same four sets of visual stimuli (Figures 1–4), but 
did not show activation with all pictures (Table 6). Patient CC 
30
parahipposcampal 
gyrus    
31 post cingulate gyrus       
32
33 ant cingulate gurys          
34
35
36
37 inf temp cortex          
38
39
L superior temporal 
gyrus
40 L inf parietal cortex    
41
42
43
44
45 R inferior frontal   
46 R mid frontal cortex   
47
L Inferior frontal 
gyrus          
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(depression) did not have activation for image 1, and patient 
DD (anxiety) did not have activation for images 2 and 3. This 
difference may be due to the nature of their underlying adverse 
reaction to INF (depression for CC and agitation/anxiety for DD), 
or due to a number of other factors, including individual-speciﬁ  c 
perceptions of these affective photographs. The differences may 
disappear or become more understandable as we increase the 
number of individuals enrolled in the protocol and tested.
Table 7 shows that there was fair agreement on areas 
of brain activation for the one picture (test image #4) that 
stimulated both patients who developed clinically signiﬁ  cant 
mood disorder, although there were areas that uniquely stimu-
lated either patient CC or patient DD. Whether this is disease 
(depression vs. agitation) dependent, related more to the test 
subject, or other variables will hopefully be better understood 
as we increase the numbers of persons imaged.
At each ofﬁ  ce visit, we routinely ask all patients in the 
HCV clinic about the presence of agitation, aggression, 
depression, drug seeking, headache, insomnia, suicidal ide-
ation and other symptoms. Reports indicate that between 10% 
and 40% of patients on INF experience depressive symptoms, 
and that interferon dosage must be reduced in many of these 
of patients and discontinued in 5%–15% because of severe 
side effects (Meyers et al 1991; Pavol et al 1995; Roche PI 
2007). Our own observation in a patient population of over 
280, with 110 patients under treatment with INF for HCV is 
that approximately 5%–10% experience INF-induced depres-
sion. We are analyzing our patient data to try and account for 
this apparently milder depressive proﬁ  le in our clinic.
Our data extends the application of fMRI as a monitoring 
tool for medication-induced depression. Building on these initial 
encouraging results, we plan to image more HCV patients receiv-
ing INF to increase the data sets. We are investigating the dose-
response of interferon to fMRI indices of clinical depression, and 
studying the therapeutic response of SSRI meds and INF dose 
reductions as treatment of INF-induced depression.
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